Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Total Non-Current Liabilities: 2020-2025

Historic Total Non-Current Liabilities for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Sep 2025 value amounting to $9.2 million.

  • Insight Molecular Diagnostics' Total Non-Current Liabilities fell 22.11% to $9.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.2 million, marking a year-over-year decrease of 22.11%. This contributed to the annual value of $9.6 million for FY2024, which is 2.62% up from last year.
  • Per Insight Molecular Diagnostics' latest filing, its Total Non-Current Liabilities stood at $9.2 million for Q3 2025, which was up 8.28% from $8.5 million recorded in Q2 2025.
  • Over the past 5 years, Insight Molecular Diagnostics' Total Non-Current Liabilities peaked at $24.2 million during Q2 2021, and registered a low of -$11.1 million during Q1 2023.
  • For the 3-year period, Insight Molecular Diagnostics' Total Non-Current Liabilities averaged around $8.2 million, with its median value being $9.8 million (2024).
  • In the last 5 years, Insight Molecular Diagnostics' Total Non-Current Liabilities crashed by 164.41% in 2023 and then surged by 197.40% in 2024.
  • Quarterly analysis of 5 years shows Insight Molecular Diagnostics' Total Non-Current Liabilities stood at $17.7 million in 2021, then decreased by 16.02% to $14.8 million in 2022, then slumped by 36.65% to $9.4 million in 2023, then rose by 2.62% to $9.6 million in 2024, then fell by 22.11% to $9.2 million in 2025.
  • Its Total Non-Current Liabilities stands at $9.2 million for Q3 2025, versus $8.5 million for Q2 2025 and $11.8 million for Q1 2025.